Research use only The CJC-1295/Ipamorelin Blend combines two well-studied peptides that act synergistically on growth hormone pathways. CJC-1295 (a modified GHRH analogue) stimulates pulsatile release of growth hormone, while Ipamorelin (a selective ghrelin receptor agonist) enhances this effect without significantly impacting cortisol, prolactin, or ACTH levels. Together, they provide a potent and selective model for investigating growth hormone dynamics, tissue repair, metabolism, and age-related endocrine decline in preclinical research.
